Reference

- Agarwal A., Juyal N., Kukreti G., Yadav S., **(2012)**, Niosomes as targeted drug delivery systems, **12(1)**, 53-60
- Allen B. R., **(2002)**, Tacrolimus ointment: Its place in the therapy of atopic dermatitis, J allergy Clin Immunol, **109,** 401-403
- Alsarra I.A., Bosele A.A., Ahmed S.M., Mahrous G.M., **(2005),** Proniosomes as a drug carrier for transdermal delivery of ketorolac, European Journal of Pharmaceutics and Biopharmaceutics, **59**, 485–490
- Anderson R, Lukey P.T, Dippenaar U, Eftychis H.A, Findlay G.H,Wooten M.W, et al., **(1987),** Dithranol mediates pro-oxidative Inhibition of Polymorphonuclear leukocyte migration and lymphocyte pro liferation Br J Dermatol, **117(4),** 405-18.
- Armstrong A.W, Robertson A.D, Wu J, et al., **(2013)**, Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol, **149,** 1180.
- Babu V. L., Mathew S.T.,. Jayaveera K..N., Prasanth V.V. **(2013),** Niosomes – vesicular drug delivery system, Int J Pharm **3(1):** 180-185
- Barakat H.S., Darwish I. A., Khordagui L. K. E. , Khalafallah N.M., **(2009),** Development of Naftifine Hydrochloride Alcohol-Free Niosome Gel, Drug Development and Industrial Pharmacy, **35**,631–637
- Bhargava T., Ramchandani U., Shrivastava S. K., Dubey P.K., **(2011),** Current Trends In NDDS With Special Reference To NSAIDS, **2 (1)**, 92-114
- Boguniewicz M., Eichenfield L.F., Hultsch T., Colo D., Diego S., Calif, Mainz, **(2003),** Current management of atopic dermatitis and interruption of the atopic march, J. allergy clin immunol, **112(6),**140-150
- Cavey D, Caron J.C, Shroot B., **(1981),** Anthralin:chemical instability and glucose-6-phosphate dehydrogenase inhibition. J Pharm Sci, **71(9),** 980-3.
- Chandra A., and Sharma P. K., **(2008),** Proniosomes based drug delivery system of piroxicam, African Journal of Pharmacy and Pharmacology, **2(9),** 184-190
- Clark, A.R., **(2000),** Topical noncorticosteroid therapies for psoriasis. Curr. Probl. Dermatol., **12**, 230–232.
- Dhiman S., Kaur H., Arora S. , **(2012),** Niosomes: A Novel Drug Delivery System, Int. J. Pharm. Sci. Rev. Res., **15(1), 22**,113-120

- Dubey A. Bini K.B., , Prabhakar P., Kamath J.V, **(2012)**, Development and Characterization of Non-Ionic Surfactant Vesicles (Niosomes) for Oral delivery of Lornoxicam, IJDDR, **4 (3),** 147-154
- Endzweig-Gribetz CH, Brady C, Lynde C Sibbald D, Lebwohl M**. (2002),** Drug
- Fonacier L. S., Dreskin S. C., Leung D. Y. M., Mineola N.Y., Aurora , Denver, Colo , **(2009),** Allergic skin diseases , J Allergy Clin Immunol ,125, **(2),** S138-149
- Forman S.B., **(2007**), Miscellaneous topical agents. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE. (Ed), Elsevier, 775
- Fuchs J, Milbradt R, Zimmer G. **(1990),** Multifunctional analysis of the interaction of anthralin and its metabolites anthraquinone and athralin dimmer with the inner mitochondrial membrane,Arch Dermatol , **282(1),** 47-55.
- Gordon K.B., Ruderman, E.M., (**2006)**, The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach. J. Am. Acad. Dermatol. **54,** S86–S91.
- Goud B.A., Raju J. and Rambhau D., **(2012),** Formulation and Evaluation of Megesterol Proniosomal Systems, IJPBS, **2(2),** 67-76
- Green P.G., Kennedy C.T.C, Forbes D.R.,**(1987),** Anthralin stability in various vehicles, J Am Acad. Dermatol,**16**, 984–988,
- Gupta A., Prajapati S.K., Balamurugan M., Singh M., Bhatia D.,**(2007),** Design and Development of a Proniosomal Transdermal Drug Delivery System for Captopril, Tropical Journal of Pharmaceutical Research, **6 (2),** 687-693
- Gupta K.S, Nappinnai M, Gupta V.R.M., **(2010),** Formulation and evaluation of topical meloxicam niosomal gel. Int J Biopharm, **1,** 7-13.
- Henseler T, Christophers E., **(1985),** Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris, J Am Acad Dermatol **13**,450-6.
- Hsieh G.C, Acosta D.**(1991),** Dithranol-induced cytotoxicity in primary cultures of rat epidermal keratinocytes. I. The role of reactive oxygen species. Toxicol Appl Pharmacol **107(1),** 16-26.
- Hughes J, Rustin M.H.A**. (1999),** Corticosteroids. In: van de Kerkhof PCM, editor. textbook of psoriasis. Oxford: Blackwell Science, 148-59.
- Indian Pharmacopoeia 2010, Government of India, Ministry of Health and Family welfare, Published by The Indian Pharmacopoeia Commission Ghaziabad. **(2nd)**, 1240-1241
- Iyyanuchamy S.K., Jesubel R. B., **(2013),** Enhancement of Antibiotics in Biosystem by Niosomal Drug Delivery Method, Journal of Drug Delivery & Therapeutics, **3(2)**, 6-8

- Jain A. P., Sharma P., Pandey P., Gupta R., Roshan S., Garg A., Sahu A., Jain A.,(**2013)**, Noisome a novel approach for drug delivery system, AJPSR,**3(5) ,**18-30
- Jain N.K., Namdeo A., **(1996),** Niosomes as drug carriers, Indian J. Pharma. Sci., **58(2), 41**-46
- Jain S, Jain P, Umamaheshwari R.B, Jain N.K. **(2003),** Transfersomes – a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Dev Ind Pharm, **29(9),** 1013–1026.
- Kaur H., Dhiman S., Arora S., **(2012)** , Niosomes: a Novel drug delivery system, Int. J. Pharm. Sci. Rev. Res., **22**, 113-120
- Kemeny L, Ruzicja T, Braun-Falco O. **(1990)**, Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol , **3(1),** 1-20.
- Khan S, Tiwari T, Tyagi S, Bhowmik M, Joshi A, Dubey B, **(2012)**, Preformulation studies and Preperation of dithranol loaded solid lipid nanoparticles, Int. J. Res. Dev. Pharm. L. Sci., **1(4),** 183-188
- Kute A., Goudanavar P., Hiremath D., Reddy S.R., **(2012)** Development and Characterization of Perindopril Erbumine Loaded Proniosomal Gel, Asian J. Pharm. Tech.[AJP Tech.], **2 (2),** 54-58
- Lebwohl M. **(1999),** The role of salicylic acid in the treatment of psoriasis. Int J Dermatol., **38,** 16-24.
- Mahrous G. M., **(2010)**, Proniosomes as a drug carrier for transdermal delivery of meloxicam, Bull. Pharm. Sci., **33 (2)**, 131-140
- Malakar J., Datta P.K., Dey S.,Gangopadhyay A. and Nayak A.K., **(2011),** Proniosomes: a preferable carrier for drug delivery system, Elixir Pharmacy, **40**, 5120-5124
- Maya W., Ashar S., (**2012**) Proniosomal drug delivery systems: An overview, international journal of pharmaceutical and chemical sciences, **1 (3),** 695-707.
- Menter A, Griffiths C.E., **(2007)**, Current and future management of psoriasis. Lancet, **370**, 272.
- Menter A, Korman N.J, Elmets C.A, et al., **(2010),** Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol, **62**,114.
- Mishra S., Vasistha P., Sachdeva M.S., **(2013)** Formulation, optimization and characterization of proniosomal gel for transdermal delivery of naproxen, WJPPS, 2**(2)**, 554-569.

- Müller, K., Leukel, P., Mayer, K.K.; Wiegrebe, W., (**1995)**, Modification of DNA bases by anthralin and related compounds. Biochem. Pharmacol. **49,** 1607–1613
- Naggar V.F., Elgamal S.S., Allam A.N., **(2012)** Proniosomes as a Stable Carrier for Oral Acyclovir: Formulation and Physicochemical Characterization, Journal of American Science, **8 (9)**, 417
- Ong P.Y., Boguniewicz M., **(2008),** Atopic Dermatitis, Prim Care Clin Office Pract, **35,** 105–117
- Raab W.P., Gmeiner B.M., **(1975),** Influence of ultraviolet light, various temperatures, and zinc ions on anthralin (dithranol). Dermatologica 150:267-276
- Racz, E., Prens, E.P., (**2009)**, Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy, Expert Rev. Mol. Med. 11, 38.
- Ram A.,Thakur A., Mittal V. K., **(2012)**, Proniosomal provesicular system for transdermal Delivery of Hydralazine for Hypertension, Asian J. Phar. and Clinical Res. **5,** (3), 219-225
- Sambhakar S., Singh B., Paliwal S., Mishra P. R., **(2012)** , Sorbitol based proniosomes to improve the permeability and stability of an oral cephalosporin. Inte. J. of Drug Delivery, **4,** 236-245
- Saraceno R., Schipani C., Mazzotta A., Espositoa M., Renzo L. D., Lorenzob A. D., Chimenti S., **(2008),** Effect of anti-tumor necrosis factor- therapies on body mass index in patients with psoriasis , Pharmacological Research ,**57,** 290–295.
- Seville R.H**., (1986)**, Dithranol-based therapies. In: Mier P.D. vd KPCM, editor. Textbook of psoriasis, Edinburh, London, Melbourne, New York: Churchill Livingstone, 178-89.
- Shamsheer A.S., Sabareesh M., Khan P.R., Sai krishna P, Sudheer B., **(2011),** Formulation and Evaluation of Lisinopril Dihydrate Transdermal Proniosomal Gels., Journal of Applied Pharmaceutical Science, **01 (08)**, 181-185
- Singh C.H., Jain C P, Bairwa N. K. **(2011),** Formulation, Characterization, stability and in vitro evaluation of nimesulide niosomes Pharmacophore, **2 (3)**, 168-185
- Singla S., Harikumar S. L. and Aggarwal G., **(2012),** Proniosomes for Penetration Enhancement in Transdermal System, IJDDR, **4 (2),** 1-13
- Sudhamani.T, Priyadarisini. N, Radhakrishnan. M., (**2010),** Proniosomes A Promising Drug Carriers, International Journal of Pharm Tech Research (IJPRIF), **2(2)**, 1446-1454
- Ternowitz T. **(1987)**, The enhanced monocyte and neutrophil chemotaxis in psoriasis is normalized after treatment with psoralens plus ultraviolet A and anthralin. J Am Acad Dermatol, **16(6),** 1169-75.

- Touitou E, Dayan N, Bergelson L, Godin B Eliaz M., **(2000),** Ethosomes- novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release **65**, 403-418.
- Udasi T.A.,Wankhade V.P.,Ingle L.M., Atram S., tapar K.K., **(2013),** Proniosomes: a novel approach to vesicular drug delivery system, Int. J. of Pharmacy and Pharma.Sci. Res., **3(1)**, 1-6
- Vadlamudi H. C., M. Sevukarajan, **(2012),** Niosomal Drug Delivery System-A Review, Indo American Journal of Pharmaceutical Research, **2(9),** 2231-6876
- Zemtsov A., Hosier H., **(2013)**, A Novel Vehicle Formulation for Treatment of Inflammatory Skin Diseases, Journal of Cosmetics, Dermatological Sciences and Applications, **3**, 18-21